Alzheimer's disease has posed a significant challenge in treatment strategies, particularly regarding the amyloid-β protein. Despite 14 failed attempts targeting it between 2004 and 2021, recent years have brought success with the approval of three anti-amyloid drugs in the U.S. Since 2021, lecanemab and donanemab have shown promising results in slowing cognitive decline, sparking a reassessment of the amyloid hypothesis. However, concerns about the modest effects, costs, and potential side effects raise questions regarding the sufficiency of targeting amyloid-β as a lone strategy against Alzheimer’s disease.
Alzheimer's disease treatment has seen a recent breakthrough, with three anti-amyloid drugs approved, but questions remain about their modest effects and implications.
Success of lecanemab and donanemab suggests the amyloid hypothesis holds, yet the debate over the significance of their modest benefits and side effects continues.
Collection
[
|
...
]